Aptamers as therapeutic and diagnostic reagents: Problems and prospects

Current Opinion in Chemical Biology

Volumn 1, Issue 1, 1997, Pages 5-9

  Osborne, Scott E ^a   Matsumura, Ichiro ^a   Ellington, Andrew D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPOLYMER; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; NUCLEIC ACID;

CHEMISTRY; DRUG DESIGN; REVIEW;

BIOPOLYMERS; DRUG DESIGN; INDICATORS AND REAGENTS; NUCLEIC ACIDS;

EID: 0031152065     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1367-5931(97)80102-0     Document Type: Article

References (34)

1. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
2. Ellington AD, Szostak JW: In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
3. Osborne SE, Ellington AD: Nucleic acid selection and the challenge of combinatorial chemistry. Chem Rev 1997, in press. This is a comprehensive review of the entire field of nucleic acid selection, and provides insight as to where the field of in vitro selection is headed.
4. Uphoff KW, Bell SD, Ellington AD: In vitro selection of aptamers: the dearth of pure reason. Curr Opin Struct Biol 1996, 6:281-288.
5. Gold L, Polisky B, Uhlenbeck O, Yarus M: Diversity of oligonucleotide functions. Annu Rev Biochem 1995, 64:763-797. This review provides a summary of SELEX work carried out at NeXstar.
6. Bartel DP, Zapp ML, Green MR, Szostak JW: HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell 1991, 67:529-536.
7. Latham JA, Johnson R, Toole JJ: The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2′-deoxyuridine. Nucleic Acids Res 1994, 22:2817-2822.
8. Lin Y, Qiu Q, Gill SC, Jayasena SD: Modified RNA sequence pools for in vitro selection. Nucleic Acids Res 1994, 22:5229-5234.
9. Smith D, Kirschenheuter GP, Charlton J, Guidot DM, Repine JE: In vitro selection of RNA-based irreversible inhibitors of human neutrophil elastase. Chem Biol 1995, 2:741-750. This paper describes the coupling of a small organic ligand to an RNA pool; the ligand directs the selection of aptamers that bind to and covalently modify the active-site of an enzyme.
10. Jensen KB, Atkinson BL, Willis MC, Koch TH, Gold L: Using in vitro selection to direct the covalent attachment of human immunodeficiency virus type 1 Rev protein to high-affinity RNA ligands. Proc Natl Acad Sci USA 1995, 92:12220-12224. The authors generate aptamers that are high-affinity binders and are able to photo-cross-link to their target. One of the aptamers can cross-link without photons, using the surface chemistry of the protein.
11. Orgel LE: Selection in vitro. Proc Royal Soc London Ser B: Biol Sci 1979, 205:435-442.
12. Jellinek D, Lynott CK, Rifkin DB, Janjic N: High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proc Natl Acad Sci USA 1993, 90:11227-11231.
13. Jellinek D, Green LS, Bell C, Janjic N: Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 1994, 33:10450-10456.
14. Jellinek D, Green LS, Bell C, Lynott CK, Gill N, Vargeese C, Kirschenheuter G, McGee DPC, Abesinghe P, Pieken WA et al.: Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 1995, 34:11363-11372.
15. Green LS, Jellinek D, Bell C, Beebe LA, Feistner BD, Gill SC, Jucker FM, Janjic N: Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 1995, 2:683-695. This paper describes several nucleotide modifications that improve both the affinity and the stability of RNA aptamers. The characterization and analysis of selected sequences is an excellent example of how aptamers can become more like pharmaceutical reagents.
16. Conrad R, Keranen LM, Ellington AD, Newton AC: Isozyme-specific inhibition of protein kinase C by RNA aptamers. J Biol Chem 1994, 269:32051-32054.
17. Schneider DJ, Feigon J, Hostomsky Z, Gold L: High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 1995, 34:9599-9610. The authors describe a good example of how DNA as well as RNA aptamers can be selected.
18. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992, 355:564-566.
19. Griffin LC, Tidmarsh GF, Bock LC, Toole JJ, Leung LL: In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 1993, 81:3271-3276.
20. Pan W, Craven RC, Qiu Q, Wilson CB, Wills JW, Golovine S, Wang JF: Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc Natl Acad Sci USA 1995, 92:11509-11513. This paper constitutes an interesting demonstration that supramolecular architectures as well as proteins can be targets for in vitro selection experiments.
21. Symensma TL, Giver L, Zapp M, Takle GB, Ellington AD: RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo. J Virol 1996, 70:179-187. This paper describes an excellent example of how aptamers selected to bind a ligand in vitro can be used as a mimetic in vivo.
22. Good PD, Kirkos AJ, Li SXL, Bertrand E, Lee NS, Giver L, Ellington AD, Zaia JA, Rossi JJ, Engelke DR: Expression of small, therapeutic RNAs in human cell nuclei. Gene Therapy 1996, 4:45-54.
23. Wiegand TW, Williams PB, Dreskin SC, Jouvin MH, Kinet JP, Tasset D: High-affinity oligonucleotide ligands to human IgE inhibit binding to FcεReceptor I. J Immunol 1996, 157:221-230.
24. Pagratis NC, Bell C, Chang Y-C, Jennings S, Fitzwater T, Jellinek D, Dang C: Potent 2′-amino, and 2′-fluoro-2′-deoxyribonucleotide inhibitors of keratinocyte growth factor. Nature Biotechnol 1997, 15:68-73.
25. Eaton BE, Gold L, Zichi DA: Let's get specific: the relationship between specificity and affinity. Chem Biol 1995, 2:633-638.
26. Chen H, McBroom DG, Zhu YQ, Gold L, North TW: Inhibitory RNA ligand to reverse transcriptase from feline immunodeficiency virus. Biochemistry 1996, 35:6923-6930. This paper discusses how SELEX-derived ligands may evade viral mutations that confer resistance to other drugs.
27. Osborne SE, Völker J, Stevens SY, Breslauer KJ, Glick GD: Design, synthesis, and analysis of disulfide cross-linked DNA duplexes. J Am Chem Soc 1996, 118:11993-12003. This paper is one of a series of articles describing the use of disulfide cross-links to conformationally stabilize oligonucleotides.
28. Letsinger RL, Wu T: Use of a stilbenediçarboxamide bridge in stabilizing, monitoring, and photochemically altering folded conformations of oligonucleotides. J Am Chem Soc 1995, 117:7323-7328.
29. Macaya RF, Waldron JA, Beutel BA, Gao H, Joesten ME, Yang M, Patel R, Bertelsen AH, Cook AF: Structural and functional characterization of potent antithrombic oligonucleotides possessing both quadraplex and duplex motifs. Biochemistry 1995, 34:4478-4492.
30. Conrad R, Ellington AD: Detecting immobilized protein kinase C isozymes with RNA aptamers. Anal Biochem 1996, 242:261-265.
31. Drolet DW, Moon-McDermott L, Romig TS: An enzyme-linked oligonucleotide assay. Nat Biotechnol 1996, 14:1021-1025. This article shows how aptamers can replace antibodies in the widely used enzyme-linked immunosorbent assay (ELISA). When aptamers are used as diagnostic reagents, measurements are both quantitative and accurate.
32. Davis KA, Abrams B, Lin Y, Jayasena SD: Use of a high affinity DNA ligand in flow cytometry. Nucleic Acids Res 1996, 24:702-706. This study shows that the emission intensity of a fluorescein depends on the way it is conjugated to the aptamer, and that successfully modified aptamers can be as sensitive as modified antibodies.
33. Lin Y, Padmapriya A, Morden KM, Jayasena SD: Peptide conjugation to an in vitro-selected DNA ligand improves enzyme inhibition. Proc Natl Acad Sci USA 1995, 92:11044-11048.
34. Nelson JS, Giver L, Ellington AD, Letsinger RL: Incorporation of a non-nucleotide bridge into hairpin oligonucleotides capable of high-affinity binding to the Rev protein of HIV-1. Biochemistry 1996, 35:5339-5344. This paper addresses the consequences of minimizing anti-Rev aptamers with chemical constraints.